Skip to main content
Log in

Imaging the glutamatergic system in vivo – relevance to schizophrenia

  • Review Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract.

Schizophrenia is a devastating psychiatric illness. Its pathophysiology is not fully clarified. Animal data, in vitro and indirect in vivo imaging support glutamatergic N-methyl-D-aspartate (NMDA) receptor hypofunction in the disorder. A lack of suitable ligands has obstructed direct evaluation of the NMDA receptor hypofunction hypothesis of schizophrenia. Many research groups are working towards developing appropriate single-photon emission tomography and positron emission tomography ligands for the NMDA receptor. This paper briefly presents evidence for links between glutamatergic system dysfunction and schizophrenia. It reviews the radioligands to evaluate glutamatergic receptors in vivo and discusses issues in developing novel ligands for the glutamatergic system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bressan, R., Pilowsky, L. Imaging the glutamatergic system in vivo – relevance to schizophrenia. Eur J Nucl Med 27, 1723–1731 (2000). https://doi.org/10.1007/s002590000372

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002590000372

Navigation